DK1713475T3 - 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet - Google Patents

1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet

Info

Publication number
DK1713475T3
DK1713475T3 DK05707857T DK05707857T DK1713475T3 DK 1713475 T3 DK1713475 T3 DK 1713475T3 DK 05707857 T DK05707857 T DK 05707857T DK 05707857 T DK05707857 T DK 05707857T DK 1713475 T3 DK1713475 T3 DK 1713475T3
Authority
DK
Denmark
Prior art keywords
pyrazole derivatives
trisubstituted
dihydro
antagonistic activity
compounds
Prior art date
Application number
DK05707857T
Other languages
Danish (da)
English (en)
Inventor
Josephus H M Lange
Cornelis G Kruse
Stuivenberg Herman H Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of DK1713475T3 publication Critical patent/DK1713475T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK05707857T 2004-01-30 2005-01-27 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet DK1713475T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53998304P 2004-01-30 2004-01-30
EP04100338 2004-01-30
PCT/EP2005/050339 WO2005074920A1 (en) 2004-01-30 2005-01-27 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Publications (1)

Publication Number Publication Date
DK1713475T3 true DK1713475T3 (da) 2008-12-01

Family

ID=34839806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05707857T DK1713475T3 (da) 2004-01-30 2005-01-27 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet

Country Status (21)

Country Link
EP (1) EP1713475B1 (zh)
JP (1) JP4693787B2 (zh)
KR (1) KR20060131861A (zh)
CN (1) CN100563651C (zh)
AT (1) ATE402697T1 (zh)
AU (1) AU2005210163B2 (zh)
BR (1) BRPI0507005A (zh)
CA (1) CA2552940A1 (zh)
DE (1) DE602005008555D1 (zh)
DK (1) DK1713475T3 (zh)
ES (1) ES2311972T3 (zh)
HK (1) HK1099688A1 (zh)
HR (1) HRP20080549T3 (zh)
IL (1) IL176547A (zh)
MX (1) MXPA06008593A (zh)
NO (1) NO20063866L (zh)
PL (1) PL1713475T3 (zh)
PT (1) PT1713475E (zh)
RU (1) RU2360904C2 (zh)
SI (1) SI1713475T1 (zh)
WO (1) WO2005074920A1 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743888A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009687A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
EP1757588A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator
WO2007009720A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
EP1745783A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
ES2337005B1 (es) * 2005-07-15 2011-01-10 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
EP1749819A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrates
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
WO2007009712A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
ES2330992B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina heterociclilsustituidos, su preparacion y uso como medicamentos.
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009705A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
EP1757589A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Amorphous phase of a substituted pyrazoline, its preparation and use as medicament
WO2007017126A2 (en) * 2005-07-29 2007-02-15 Laboratorios Del Dr. Esteve, S.A. POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
ES2326357B1 (es) * 2005-07-29 2010-04-21 Laboratorios Del Dr. Esteve, S.A. Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento.
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
ES2330071B1 (es) * 2007-01-15 2010-07-05 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.
EP1946777A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline for preventing weight gain
ES2328653B1 (es) * 2007-01-15 2010-05-28 Laboratorios Del Dr. Esteve S.A. Combinacion de sustancias activas para el tratamiento de la diabetes.
EP1944295A1 (en) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
EP1946778A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Active substance combination for the treatment of diabetes
EP1946779A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Combination of substituted pyrazolines and agent for treating dyslipidemia
EP1947089A1 (en) * 2007-01-18 2008-07-23 Laboratorios del Dr. Esteve S.A. A-polymorph of a substituted pyrazoline, its preparation and use as medicaments
EA201070019A1 (ru) * 2007-06-15 2010-06-30 Солвей Фармасьютикалс Б.В. 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
US8410135B2 (en) 2007-06-15 2013-04-02 Solvay Pharmaceuticals B.V. 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
KR20100072037A (ko) 2007-09-20 2010-06-29 애보트 헬스케어 프로덕츠 비.브이. 칸나비노이드 ｃｂ₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1ｈ)-피라졸
EP2042175A1 (en) * 2007-09-21 2009-04-01 Laboratorios del Dr. Esteve S.A. Dose regimens of CB1-Receptor ligands in the treatment of obesity
AR071487A1 (es) * 2008-04-23 2010-06-23 Solvay Pharm Bv Derivados de (5r)-1,5-diaril-4,5-dihidro-1h-pirazol-3-carboxamidina que tienen actividad antagonista cb1
US9765031B2 (en) 2012-11-13 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
WO2014208939A1 (en) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
AU2015255765A1 (en) * 2014-05-09 2016-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543930A1 (en) * 1990-08-17 1993-06-02 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
JPH07504658A (ja) * 1992-03-02 1995-05-25 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺節足動物性アミド類
MXPA02009258A (es) * 2000-03-23 2005-04-19 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1.
SI1373216T1 (en) * 2001-03-22 2005-06-30 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
DK1429761T3 (da) * 2001-09-21 2007-02-05 Solvay Pharm Bv Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
KR100950430B1 (ko) * 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체

Also Published As

Publication number Publication date
HRP20080549T3 (en) 2008-11-30
CN100563651C (zh) 2009-12-02
EP1713475A1 (en) 2006-10-25
RU2006131132A (ru) 2008-03-10
KR20060131861A (ko) 2006-12-20
RU2360904C2 (ru) 2009-07-10
AU2005210163B2 (en) 2010-05-13
IL176547A0 (en) 2006-10-31
IL176547A (en) 2010-06-30
MXPA06008593A (es) 2006-08-28
PL1713475T3 (pl) 2009-03-31
JP2007519686A (ja) 2007-07-19
EP1713475B1 (en) 2008-07-30
PT1713475E (pt) 2008-11-10
WO2005074920A1 (en) 2005-08-18
ES2311972T3 (es) 2009-02-16
SI1713475T1 (sl) 2008-12-31
NO20063866L (no) 2006-10-27
CN1913885A (zh) 2007-02-14
ATE402697T1 (de) 2008-08-15
HK1099688A1 (en) 2007-08-24
DE602005008555D1 (de) 2008-09-11
JP4693787B2 (ja) 2011-06-01
BRPI0507005A (pt) 2007-06-05
AU2005210163A1 (en) 2005-08-18
CA2552940A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
DK1713475T3 (da) 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
DE602005007350D1 (de) Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2004013120A8 (en) Novel benzodioxoles
SG153811A1 (en) Quinazolinone derivatives useful as vanilloid antagonists
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
UA85079C2 (en) Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
NO20070089L (no) DPP-IV inhibitorer
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
TW200745039A (en) Isotopically substituted pantoprazole
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
TNSN07006A1 (en) Novel heterocyclic compounds
TW200628153A (en) Novel compounds
TW200600013A (en) 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
MX2007007554A (es) Oxiarenos sustituidos.
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists
EA201070381A1 (ru) 5-арил-4,5-дигидро-(1н)-пиразолы в качестве агонистов каннабиоидного сврецептора